C4 Therapeutics, Inc. Receives Average Recommendation of Moderate Buy from Analysts - MarketBeat
CCCC Stock | USD 3.95 0.10 2.60% |
About 71 percent of all C4 Therapeutics' shareholders are curious in acquiring. The analysis of the overall investor sentiment regarding C4 Therapeutics suggests that quite a large number of traders are confidant. The current market sentiment, together with C4 Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use C4 Therapeutics stock news signals to limit their universe of possible portfolio assets.
CCCC |
C4 Therapeutics, Inc. Receives Average Recommendation of Moderate Buy from Analysts MarketBeat
Read at news.google.com
C4 Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards C4 Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
C4 Therapeutics Fundamental Analysis
We analyze C4 Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of C4 Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of C4 Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Liabilities
Current Liabilities Comparative Analysis
C4 Therapeutics is currently under evaluation in current liabilities category among its peers. Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
C4 Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with C4 Therapeutics stock to make a market-neutral strategy. Peer analysis of C4 Therapeutics could also be used in its relative valuation, which is a method of valuing C4 Therapeutics by comparing valuation metrics with similar companies.
Peers
C4 Therapeutics Related Equities
PRLD | Prelude Therapeutics | 46.07 | ||||
STTK | Shattuck Labs | 10.58 | ||||
GLUE | Monte Rosa | 6.45 | ||||
CGEM | Cullinan Oncology | 5.94 | ||||
IPSC | Century Therapeutics | 4.76 | ||||
MLYS | Mineralys Therapeutics, | 4.31 | ||||
KYMR | Kymera Therapeutics | 3.88 | ||||
RZLT | Rezolute | 3.68 | ||||
ARVN | Arvinas | 3.65 | ||||
RVMD | Revolution Medicines | 1.78 | ||||
FHTX | Foghorn Therapeutics | 1.43 | ||||
EWTX | Edgewise Therapeutics | 0.06 | ||||
NRIX | Nurix Therapeutics | 1.05 |
Complementary Tools for CCCC Stock analysis
When running C4 Therapeutics' price analysis, check to measure C4 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C4 Therapeutics is operating at the current time. Most of C4 Therapeutics' value examination focuses on studying past and present price action to predict the probability of C4 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C4 Therapeutics' price. Additionally, you may evaluate how the addition of C4 Therapeutics to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |